Jul 9, 1981

Acyclovir prophylaxis of herpes-simplex-virus infections

The New England Journal of Medicine
R SaralP S Lietman

Abstract

We conducted a double-blind, placebo-controlled study of acyclovir prophylaxis against infection with herpes simplex virus (HSV) in 20 seropositive recipients of bone-marrow transplants. Acyclovir or placebo was administered for 18 days, starting three days before transplantation. Culture-positive HSV lesions developed during the study in seven of the 10 patients who received placebo. In contrast, no such lesions appeared in the 10 patients who received acyclovir (P congruent to 0.003). None of the patients had evidence of drug toxicity. Five of the patients treated with acyclovir had mild culture-positive HSV infections after cessation of the drug, and two additional patients shed virus without having lesions. Acyclovir appears to be a potent inhibitor of HSV replication. Although acyclovir does no appear to eradicate latent infection, it can provide effective prophylaxis against reactivated infections.

  • References20
  • Citations227

Citations

Mentioned in this Paper

Guanine
Neonatal Herpes
Latent Tuberculosis
Clinical Trials
Transplantation, Homologous
Bone Marrow Cell Transplantation
Cytomegalovirus Infections
Drug Toxicity
Herpes Simplex Infections
Double-Blind Method

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.